Replies to post #247032 on Biotech Values

[Mufaso]

Thank you- you are correct. I had trouble formatting the post using Ihub tools. Maybe the improvements coming will make tables like this easier to format/read. I redid the table of failed NASH drugs with trialcompleted and your corrections on MOA below:

 Selonsertib (Gilead)		ASK1 inhibitor		Multiple Ph 3  
 Simtuzumab  (Gilead)		Anti-Loxl2 MAb		Ph 2  
 Px-102 (Gilead)		FXR agonist		Ph 2  
 Elafibranor (Genfit)		PPARa/d agonist		Ph 3  
 Emricasan (Conatus)		pan-caspase inh		Ph 2b  
 Ocaliva (Intercept ) 		FXR agonist		Mult Ph 3  
 Seladelpar (Cymabay ) 		PPAR-delta agonist	Ph 2b  
 Semaglutide (NOVO) 		GLP-1 ag		Ph 2  
 PF-06882961 (Pfizer)		GLP-1 ag		Ph 1 
 PF 06835919 (Pfizer)		Ketohexokinase inh	Ph 2 
 NGM-219 (NGM     )		UPR inducer		Ph 2b 
 BI 1467335(Boehringer)		Pan-caspase inh		ph 2